XGN analyst estimates
Exagen (XGN) analyst ratings, the average price target and its range, and every firm's latest call.
XGN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | Exagen price target raised to $11 from $9 at Canaccord | $11.00 |
| Jun 24, 2026 | Roth Capital | Exagen initiated with a Buy at Roth Capital | $8.00 |
| May 12, 2026 | BTIG | Exagen price target lowered to $8 from $9 at BTIG | $8.00 |
| Apr 20, 2026 | Canaccord Genuity | Exagen price target lowered to $8 from $10 at Canaccord | $8.00 |
| Mar 11, 2026 | UBS | Exagen price target lowered to $10 from $12 at Craig-Hallum | $10.00 |
| Mar 10, 2026 | BTIG | Exagen (XGN) PT Lowered to $9 at BTIG | $9.00 |
| Feb 17, 2026 | BTIG | Exagen price target lowered to $10 from $15 at BTIG | $10.00 |
| Oct 27, 2025 | Canaccord Genuity | Exagen price target raised to $15 from $11 at Canaccord | $15.00 |
| Oct 14, 2025 | KeyBanc | Exagen price target raised to $15 from $12 at KeyBanc | $15.00 |
| Jul 30, 2025 | Cantor Fitzgerald | Exagen price target raised to $10 from $7 at Cantor Fitzgerald | $10.00 |
| Jul 29, 2025 | KeyBanc | Exagen upgraded to Overweight from Sector Weight at KeyBanc | $12.00 |
| Nov 12, 2024 | BTIG | BTIG Reiterates Buy Rating on Exagen (XGN) | $5.00 |
| May 14, 2024 | Canaccord Genuity | Canaccord Genuity Reiterates Buy Rating on Exagen (XGN) | $5.00 |
| Nov 17, 2022 | BTIG | BTIG Maintains Buy on Exagen, Lowers Price Target to $7 | $7.00 |
- 6 firms rate XGN: 6 buy, 0 hold, 0 sell.
- The average price target is $9.00 from None analysts, from $8.00 to $11.00.
Updated 2026-11-11 00:48 UTC